Heron Therapeutics has rallied nearly 19% in a week — but short sellers are not flinching.
That tension defines the setup heading into Q1 results. The stock closed at $1.21 on April 28, up 54% over the past month. Yet short interest has climbed alongside the price, rising 3.8% week-on-week to 22.4% of the free float. The divergence between price action and positioning is the clearest signal in the data right now.
The lending market tells a story of growing but not extreme conviction on the short side. About 70% of available shares to borrow are currently lent out — up from roughly 64% in mid-March, but still well below the 52-week peak of 96.4%. Availability has tightened to around 49% of short interest, meaning there is roughly one share available for every two already borrowed. That is tight but not a squeeze threshold. Cost to borrow remains modest at 1.04%, barely changed over the month, confirming that borrow supply is uncomfortable but not scarce. Options positioning has shifted noticeably in the other direction: the put/call ratio dropped to 1.27, nearly 2.5 standard deviations below its 20-day average of 1.42. That is the most call-heavy the options market has been since before late March, suggesting some traders are buying the rally rather than hedging against it. The contrast between a rising short base and a declining put/call ratio reflects a genuine split in the market.
The Street is equally unresolved. Both active analyst firms — HC Wainwright and Needham — carry Buy ratings, with a mean price target near $4.33. That implies more than 250% upside to Tuesday's close. However, HC Wainwright cut its earnings estimates in the past week, and the Zacks model moved to a Strong Sell rating on April 29. The ORTEX short score is elevated at 84.4, ranking HRTX in the first percentile of all stocks on that measure — meaning almost no stock in the universe carries a more bearish short-positioning profile. Days-to-cover ranks in the second percentile. The bull case centres on ZYNRELEF's opioid-sparing profile and expanding Crosslink partnership momentum. Bears point to Sustol's structural revenue decline as generic palonosetron takes share, and a history of cash burn that has not yet resolved.
Institutional ownership adds nuance. Rubric Capital Management holds 15.9% of shares outstanding and added nearly one million shares last quarter. Clearline Capital added 2.5 million shares. Millennium Management built a position of nearly seven million shares in the same period. Against that active accumulation, Palisade Capital trimmed by roughly one million shares. The concentration of activist-leaning and healthcare-specialist holders at the top of the register suggests the stock is not simply a passive index play — there is genuine conviction on both sides of the institutional ledger.
Heron reports Q1 results on May 11. The most recent earnings print — in February — produced a 10% one-day gain followed by a 5.6% five-day retreat. That pattern of an initial pop giving way to selling pressure is worth tracking. The next print will likely turn on ZYNRELEF revenue trajectory and any update to the Crosslink commercial ramp, with the Sustol erosion rate as the key variable the bears will be watching most closely.
See the live data behind this article on ORTEX.
Open HRTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
